Effects of HDL-modifiers on cardiovascular outcomes: A meta-analysis of randomized trials

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 25, Issue 1, 2015, Pages 9-23

  Verdoia, M ^a   Schaffer, A ^a   Suryapranata, H ^b   De Luca, G ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular mortality; CETP inhibitors; HDL cholesterol; Niacin

Indexed keywords

ANACETRAPIB; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; EVACETRAPIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; TORCETRAPIB; CETP PROTEIN, HUMAN; CHOLESTEROL ESTER TRANSFER PROTEIN; HYPOCHOLESTEROLEMIC AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY RECANALIZATION; DATA EXTRACTION; DIABETES MELLITUS; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; META ANALYSIS; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; VALIDITY; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; COMPARATIVE STUDY; DIET SUPPLEMENTATION; DIET THERAPY; MORTALITY; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; RISK; STROKE;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; DIABETES MELLITUS; DIETARY SUPPLEMENTS; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION; NIACIN; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; STROKE;

EID: 84921340591     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2014.09.003     Document Type: Article

References (67)

1. De Luca G., Cassetti E., Marino P. Percutaneous coronary intervention-related time delay, patient's risk profile, and survival benefits of primary angioplasty vs lytic therapy in ST-segment elevation myocardial infarction. Am J Emerg Med 2009, 27:712-719.
2. Navarese E.P., De Luca G., Castriota F., Kozinski M., Gurbel P.A., Gibson C.M., et al. Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. J Thromb Haemost 2011 Oct, 9(10):1902-1915.
3. De Luca G., Suryapranata H., Marino P. Reperfusion strategies in acute ST-elevation myocardial infarction: an overview of current status. Prog Cardiovasc Dis 2008, 50:352-382.
4. De Luca G., Smit J.J., Ernst N., Suryapranata H., Ottervanger J.P., Hoorntje J.C., et al. Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Thromb Haemost 2005, 93:820-823.
5. De Luca G., Gibson C.M., Bellandi F., Noc M., Dudek D., Zeymer U., et al. Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors. Atherosclerosis 2009, 207:181-185.
6. De Luca G., Gibson C.M., Gyöngyösi M., Zeymer U., Dudek D., Arntz H.R., et al. Gender-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation. J Thromb Thrombolysis 2010, 30:342-346.
7. De Luca G., Maas A.C., Suryapranata H., Ottervanger J.P., Hoorntje J.C., Gosselink A.T., et al. Prognostic significance of residual cumulative ST-segment deviation after mechanical reperfusion in patients with ST-segment elevation myocardial infarction. Am Heart J 2005, 150:1248-1254.
8. Okrainee K., Banerjee D.K., Eisenberg M.J. Coronary artery disease in the developing world. Am Heart J 2004, 148:7-15.
9. Nicholls S.J., Ballantyne C.M., Barter P.J. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011, 365:2078-2087.
10. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
11. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
12. Martin S.S., Metkus T.S., Horne A., Blaha M.J., Hasan R., Campbell C.Y., et al. Waiting for the National Cholesterol Education Program Adult Treatment Panel IV Guidelines, and in the meantime, some challenges and recommendations. Am J Cardiol 2012, 110:307-313.
13. Uchechukwu K.S., Fazio S., MacRae F.L. residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep 2012, 14:1-10.
14. Khera A.V., Cuchel M., de la Llera-Moya M., Rodrigues A., Burke M.F., Jafri K., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011, 364:127-135.
15. Rosenson R.S. Low HDL-C: a secondary target of dyslipidemia therapy. Am J Med 2005, 118:1067-1077.
16. Morris D.L., Kritchevsky S.B., Davis C.E. Serum carotenoids and coronary heart disease. The lipid research clinics coronary primary prevention trial and follow-up study. JAMA 1994, 272:1439-1441.
17. Stamler J., Neaton J.D., Cohen J.D., Cutler J., Eberly L., Grandits G., MRFIT Research Group, et al. Multiple risk factor intervention trial revisited: a new perspective based on nonfatal and fatal composite endpoints, coronary and cardiovascular, during the trial. J Am Heart Assoc 2012, 5:e003640.
18. Bruckert E., Labreuche J., Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010, 210:353-361.
19. Lee J.M., Robson M.D., Yu L.M., Shirodaria C.C., Cunnington C., Kylintireas I., et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009, 54:1787-1794.
20. Lavigne P.M., Karas R.H. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol 2013, 61(4):440-446.
21. Larach D.B., deGoma E.M., Rader D.J. Targeting high density lipoproteins in the prevention of cardiovascular disease?. Curr Cardiol Rep 2012 Dec, 14(6):684-691.
22. Nicholls S.J. Is niacin ineffective? Or did AIM-HIGH miss its target?. Cleve Clin J Med 2012, 79:38-43.
23. Katz P.M., Leiter L.A. Drugs targeting high-density lipoprotein cholesterol for coronary artery disease management. Can J Cardiol 2012, 28:667-677.
24. Mitka M. Researchers still seek clinical benefit in raising levels of good cholesterol. JAMA 2012, 307(1):21-22.
25. Arteaga A., Rigotti A. Cholesteryl ester transfer protein inhibition in the management of atherosclerotic cardiovascular disease: second act & a rebirth of hope. Rev Med Chil 2011, 139:802-806.
26. De Luca G., Suryapranata H., Stone G.W., Antoniucci D., Biondi-Zoccai G., Kastrati A., et al. Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials. Int J Cardiol 2008, 126:37-44.
27. Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gøtzsche P.C., Ioannidis J.P., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009, 151:W65-W94.
28. Blankenhorn D.H., Nessim S.A., Johnson R.L., Sanmarco M.E., Azen S.P., Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987 Jun 19, 257:3233-3240.
29. Carlson L.A., Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988, 223:405-418.
30. Kane J.P., Malloy M.J., Ports T.A., Phillips N.R., Diehl J.C., Havel R.J. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990, 264:3007-3012.
31. Coronary Drug Project Research Group Clofibrate and niacin in coronary heart disease. JAMA 1975, 231:360-381.
32. Brown B., Zhao X., Chait A., Fisher L.D., Cheung M.C., Morse J.S., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583-1592.
33. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., Grace K.A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004, 110:3512-3517.
34. Taylor A., Villines T., Stanek E., Devine P.J., Griffen L., Miller M., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009, 361:2113-2122.
35. Boden W.E., Probstfield J.L., Anderson T., Chaitman BR,Desvignes-Nickens P., Koprowicz K., McBride R., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, 365:2255-2267.
36. Brown G., Albers J., Fisher L., Schaefer S.M., Lin J.T., Kaplan C., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990, 323:1289-1298.
37. Guyton J.R., Brown B.G., Fazio S., Polis A., Tomassini J.E., Tershakovec A.M. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. J Am Coll Cardiol 2008, 51:1564-1572.
38. Whitney E.J., Krasuski R.A., Personius B.E., Michalek J.E., Maranian A.M., Kolasa M.W. A randomized trial of a strategy for increasing highdensity lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005, 142:95-104.
39. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013, 34(17):1279-1291. HPS2-THRIVE Collaborative Group.
40. Cannon C.P., Shah S., Dansky H.M., Davidson M., Brinton E.A., Gotto A.M., et al. Determining the efficacy and tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010 Dec 16, 363(25):2406-2415.
41. Nicholls S.J., Brewer H.B., Kastelein J.J., Krueger K.A., Wang M.D., Shao M., et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011, 306(19):2099-2109.
42. Lüscher T.F., Taddei S., Kaski J.C., Jukema J.W., Kallend D., Münzel T., et al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J 2012, 33:857-865.
43. Barter P.J., Caulfield M., Eriksson M., Grundy S.M., Kastelein J.J., Komajda M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357(21):2109-2122.
44. Schwartz G.G., Olsson A.G., Abt M., Ballantyne C.M., Barter P.J., Brumm J., et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012, 367:2089-2099.
45. Stein E.A., Roth E.M., Rhyne J.M., Burgess T., Kallend D., Robinson J.G. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur Heart J 2010, 31:480-488.
46. De Luca G., Ernst N., van 't Hof A.W., Ottervanger J.P., Hoorntje J.C., Gosselink A.T., et al. Predictors and clinical implications of early reinfarction after primary angioplasty for ST-segment elevation myocardial infarction. Am Heart J 2006 Jun, 151(6):1256-1259.
47. De Luca G., Marino P. Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials. Am Heart J 2007 Dec, 154(6). 1085.e1-1085.6.
48. Navarese E.P., Kubica J., Castriota F., Gibson C.M., De Luca G., Buffon A., et al. Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. EuroIntervention 2011 Dec, 7(8):985-994.
49. Capozzolo C., Piscione F., De Luca G., Cioppa A., Mazzarotto P., Leosco D., et al. Direct coronary stenting: effect on coronary blood flow, immediate and late clinical results. Catheter Cardiovasc Interv 2001 Aug, 53(4):464-473.
50. Gurdasani D., Sjouke B., Tsimikas S., Hovingh G.K., Luben R.N., Wainwright N.W., et al. Ipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol 2012, 32:3058-3065.
51. Wilson P.W., Pencina M., Jacques P., Selhub J., D'Agostino R., O'Donnell C.J. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 2008, 1:92-97.
52. De Luca G., Santagostino M., Secco G.G., Cassetti E., Giuliani L., Franchi E., et al. Mean platelet volume and the extent of coronary artery disease: results from a large prospective study. Atherosclerosis 2009, 206:292-297.
53. De Luca G., Secco G.G., Santagostino M., Venegoni L., Iorio S., Cassetti E., et al. Novara Atherosclerosis Study Group (NAS). Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. Nutr Metab Cardiovasc Dis 2012, 22:426-433.
54. De Luca G., Venegoni L., Iorio S., Secco G.G., Cassetti E., Verdoia M., et al. Platelet distribution width and the extent of coronary artery disease: results from a large prospective study. Platelets 2010, 21:508-514.
55. Castelli W.P., Garrison R.J., Wilson P.W., Abbott R.D., Kalousdian S., Kannel W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 1986, 256:2835-2838.
56. Murphy S.A., Cannon C.P., Wiviott S.D., McCabe C.H., Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22) trial. J Am Coll Cardiol 2009, 54:2358-2362.
57. Pedersen T.R., Faergeman O., Kastelein J.J., Olsson A.G., Tikkanen M.J., Holme I, Larsen M.L., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005, 294:2437-2445.
58. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1433.
59. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
60. Brewer H.B. Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003, 92:23K-29K.
61. Grundy S.M., Mok H.Y., Zech L., Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 1981, 22:24-36.
62. Duggal J.K., Singh M., Attri N., Singh P.P., Ahmed N., Pahwa S., et al. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease. J Cardiovasc Pharmacol Ther 2010, 15:158-166.
63. Briel M., Ferreira-Gonzalez I., You J.J., Karanicolas P.J., Akl E.A., Wu P., et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009, 338:b92.
64. Kumar S., Rai H., Kapoor A., Tewari S., Sinha N. Pharmacological measures to increase HDL-C among high risk isolated low HDL cases: a randomized study amongst north Indians. Indian J Med Res 2013, 138(6):873-881.
65. Shao B., Oda M.N., Oram J.F., Heinecke J.W. Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol 2010, 23:447-454.
66. Pennathur S., Bergt C., Shao B., Byun J., Kassim S.Y., Singh P., et al. Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J Biol Chem 2004, 279:42977-42983.
67. Navab M., Yu R., Gharavi N. High-density lipoprotein: antioxidant and anti-inflammatory properties. Curr Atheroscler Rep 2007, 9:244-248.